Takeda Pharmaceutical Co., Japan’s largest drugmaker, forecast its biggest jump in full-year profit in six years on sales of the best-selling Actos diabetes pill.
Net income will rise 18 percent to ¥395 billion in the year ending March 31, from ¥335.8 billion a year earlier, the Osaka-based company said Monday. Actos overtook GlaxoSmithKline PLC’s Avandia as the world’s top-selling diabetes medicine after the Glaxo drug was linked in a May 21 report to a higher heart attack risk.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.